Qube Research & Technologies LTD Rocket Pharmaceuticals, Inc. Transaction History

Qube Research & Technologies LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$26.16 - $30.74 $4.64 Million - $5.46 Million	177,524 New	177,524 $4.78 Million
Q3 2023 Nov 13, 2023	SELL	$15.07 - $24.05 $2.11 Million - $3.37 Million	-139,994 Reduced 52.46%	126,862 $2.6 Million
Q2 2023 Aug 14, 2023	BUY	$16.59 - $23.6 $2.79 Million - $3.97 Million	168,207 Added 170.51%	266,856 $5.3 Million
Q1 2023 May 15, 2023	BUY	$15.79 - $22.6 $1.56 Million - $2.23 Million	98,649 New	98,649 $1.69 Million
Q2 2022 Aug 15, 2022	BUY	$7.96 - $16.64 $187,776 - $392,537	23,590 Added 75.26%	54,935 $756,000
Q1 2022 May 09, 2022	BUY	$13.16 - $23.68 $39,861 - $71,726	3,029 Added 10.7%	31,345 $497,000
Q4 2021 Feb 01, 2022	BUY	$21.52 - $36.02 $609,360 - $1.02 Million	28,316 New	28,316 $618,000
Q2 2021 Aug 13, 2021	SELL	$39.41 - $47.25 $537,946 - $644,962	-13,650 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$43.34 - $65.91 $591,591 - $899,671	13,650 New	13,650 $606,000
Q1 2020 May 15, 2020	SELL	$9.71 - $25.11 $105,120 - $271,840	-10,826 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$11.07 - $24.23 $119,843 - $262,313	10,826 New	10,826 $246,000

209

93.2M

319K

70.3K

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $987M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.